Mainz Biomed

Mainz BioMed is a molecular genetic diagnostics company that develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's molecular genetic diagnostic tools focus on early cancer detection. It markets ColoAlert, a non-invasive home test for colorectal cancer combining DNA and fecal immunochemical analysis, commercially available across Europe and the UAE. The company is advancing its pipeline with PancAlert, a PCR-based stool test for early pancreatic cancer, and has initiated pivotal FDA registration studies for a next-generation colorectal test using proprietary mRNA biomarkers, AI algorithms, and FIT components.

Domain

mainzbiomed.com

Country

Germany

Employees

51-100

Last Funding

$3.0M

Founded

2020

Frequently Asked Questions

What technologies does Mainz Biomed use?+

Mainz Biomed uses 10 technologies including Framer Motion, Svelte, Umami.

What industry is Mainz Biomed in?+

Mainz Biomed operates in the Biotechnology industry.

Where is Mainz Biomed based?+

Mainz Biomed is headquartered in Germany.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026